Podcasts about CRISPR

Microsoft reportedly plans to begin using Anthropic's latest Claude models to power some of the Copilot features in its Office 365 apps. In a report published Tuesday, The Information said the tech giant would announce the change "in the coming weeks." Microsoft currently relies on OpenAI's tech to power the majority of AI features found inside of Word, Excel, Outlook and PowerPoint. Also, the FDA approved the biotech company eGenesis to begin human trials of pig-to-human kidney transplants. eGenesis provides pigs with CRISPR-modified genes. These genetic changes reduce the chances of organ rejection in human recipients. Learn more about your ad choices. Visit podcastchoices.com/adchoices

UC Davis scientists use CRISPR to help wheat boost soil bacteria and cut fertilizer costs for farmers.

Walter Isaacson - bestselling biographer behind Musk, Einstein and Steve Jobs - in conversation with Evan Ratliff brings you behind the scenes of The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race. The story of the third great technological revolution in modern times. See omnystudio.com/listener for privacy information.

On todays show the Future Foursome talk about Google antitrust, AI developments, Starlink demand, quantum computing, biomedical advancements, autonomous vehicles, AI in sports, global warming, cybersecurity, robotics, AI in healthcare, LASIK without lasers, microplastics in blood, brain-computer interfaces, CRISPR in mosquitoes. Don't miss it!

Een nieuw Nerdland maandoverzicht! Met deze maand: Robot games! Flosdraad! Wavy Dave! Tattoos! GPT-5! Teken! Inbelmodems! Wevermieren! Garum! En veel meer... Shownotes: https://podcast.nerdland.be/nerdland-maandoverzicht-september-2025/ Gepresenteerd door Lieven Scheire met Hetty Helsmoortel, Marian Verhelst, Peter Berx, Jeroen Baert en Els Aerts. Opname, montage en mastering door Jens Paeyeneers en Els Aerts.(00:00:00) Intro (00:02:03) ROBOT OLYMPICS in Beijing (00:10:53) Iedereen wil robot olympics: ook Athene (00:12:49) Unitree R1 kost nu 6000 euro! (00:14:24) Figure robot kan wasmachine inladen (00:21:25) Neen, er is geen zwangerschapsrobot… (00:25:12) Tekenbeet kan je allergisch maken voor… vlees (00:31:00) Met Alphafold gewassen weerbaarder maken tegen bacteriën (00:36:54) Mannetje nieuwe tarantulasoort durft vrouwtje niet te benaderen (00:42:48) De inbelmodem is officieel overleden… (00:49:33) AI meets CRISPR for precise gene editing (00:54:07) Vaccin toedienen met dental floss (00:56:41) UGent doet nieuwe vaccinatietesten en zoekt vrijwilligers (01:00:04) SILICON VALLEY NEWS (01:00:22) GPT-5 stelt teleur, alweer wordt de AI crash voorspeld (01:11:41) OpenAI lanceert downloadbaar reasoning model (01:16:49) DeepSeek schakelt terug over op Nvidia chips tegen de wil van China in (01:21:38) Succesvolle 10e lancering Starship (01:24:05) X 37B gelanceerd met “quantum equipment” aan boord (01:29:00) We weten eindelijk welke vis er in garum zit (01:31:51) Krabrobot zwaait naar vioolkrabben (01:38:02) Artemis II crew doet uitgebreide testen met Orion (01:43:03) Krachtmeting van wevermieren (01:49:24) TRAPPIST – 1d is minder aardachtig dan gedacht (01:52:25) Dieet van enkel mieren is 12 keer afzonderlijk ontstaan in de evolutie (01:59:05) 2500 jaar oude tattoos gereconstrueerd, en die zijn verbazend mooi (02:04:01) Studie van vlinderstichting offline na doodsbedreiging (02:06:23) De patat is een dochter van de tomaat (02:07:51) Belgische tak van palingmaffia opgerold (02:11:13) De stormvogel poept alleen in de lucht, en niemand weet waarom (02:13:18) Aankondigingen (02:19:57) Sponsor SIEMENS

Gene therapy is no longer reserved for rare diseases or billionaire tech founders. In this episode, I sit down with Jay Spall, senior executive at MiniCircle, to discuss how gene therapy has entered a new era—one where optimizing your health, building muscle, and extending your lifespan can be done safely, affordably, and effectively.Jay shares how MiniCircle's first breakthrough product, Follistatin, uses plasmid-based delivery to boost muscle growth, reduce fat, and improve metabolic health—all from a single injection. We break down what gene therapy really is, how it compares to CRISPR, how long the effects last, and what to expect in terms of results and safety. Plus, Jay offers a look into the company's future therapies and his powerful personal journey from chronic illness to radical transformation.We cover the science, the stories, and the surprising benefits you might not expect.Interested in receiving Follistatin gene therapy? Contact our clinic, Chara Health, at 818-356-8232 or email info@chara-health.comKey Takeaways:Introduction (00:00)Jay's personal health journey and introduction to gene therapy (02:24)Minicircle's gene therapy technology and initial success (08:29)Follistatin's benefits and real-world applications (11:14)Clinical study results and broader health benefits (13:52)Muscle gain, fat loss, and strength benefits (19:08)How long does Follistatin's benefit last (22:48)How involved is Follistatin treatment (28:01)Follistatin side effects (33:08)Challenges and future directions of gene therapy (42:24)Additional Resources:If you are interested in receiving Follistatin gene therapy, please contact our clinic Chara Health at 818-356-8232, or email info@chara-health.com.✨ Connect with Jay SpallWebsite: https://minicircle.io/our-therapies/follistatin/Instagram: https://www.instagram.com/minicircledna/—✨ Learn more about how to live a long and pain-free life: https://joykongmd.com/ ✨ Follow me on Facebook: https://www.facebook.com/stemcelldrjoy/ ✨ Follow me on Instagram: https://www.instagram.com/dr_joy_kong/ —Dr. Joy Kong is a regenerative medicine and anti-aging expert. Her podcast is part of her mission to reduce suffering and elevate happiness. Join us every week for the latest holistic health insights that will help you live a long and pain-free life.

Led by Dr. Ryotaro Hashizume of the Graduate School of Medicine, Unit for Genomic Manipulation and Technology Development, the team had successfully developed a technique to eliminate the extra copy of chromosome 21 in cells derived from individuals with Down syndrome. The condition, caused by trisomy 21, affects roughly one in every 700 births and leads to intellectual disabilities and other health complications. *Apologies for the sound quality halfway through the podcast. Episode notes: ‘Mie University Researchers Develop Groundbreaking CRISPR Technique to Remove Extra Chromosome in Down Syndrome Cells': https://barrierfreejapan.com/2025/09/02/mie-university-researchers-develop-groundbreaking-crispr-technique-to-remove-extra-chromosome-in-down-syndrome-cells/

Why billionaire tech mogul Peter Thiel’s lecture series on the Antichrist is a sign that biblical end-time prophecies are stage-setting for the Rapture. Pastor Gene Pensiero Find audio, video, and text of hundreds of other prophecy updates at: https://calvaryhanford.com/prophecy Read along with us at https://calvaryhanford.substack.com Follow us on YouTube at https://youtube.com/calvaryhanford — The signs of […]

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene Podcast episode, Host Erin Harris talks to Stanford School of Medicine Ph.D. student, Yuanhao Qu, about his work developing CRISPR-GPT, an AI-driven multi-agent system designed to automate genetic experimental design and data analysis, making CRISPR experiments more efficient and accessible, even for non-experts. Qu explains how CRISPR-GPT addresses key challenges such as guide design, delivery methods, off-target prediction, and protocol generation, and shares how collaborations with Princeton helped shape the tool's architecture and evaluation. Qu also discusses Biomni, a general-purpose biomedical AI agent aimed at supporting a broad range of life science applications, and how the two systems complement each other as building blocks toward an "AI scientist" capable of accelerating discovery across biomedicine. Qu emphasizes the importance of rigorous evaluation, productivity gains, and ethical guardrails to ensure these tools are powerful yet safe for the future of biomedical research.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Ragnhild Ørstavik deler siste nytt fra de store medisinske tidsskriftene. Kokt og bakt potet ser ikke ut til å øke risikoen for type 2-diabetes (1–3). Et nytt medikament gir bedre livskvalitet for kvinner med brystkreft og overgangsplager, men langtidseffektene er fortsatt ukjente (4, 5). Vektnedgang før IVF kan øke sjansen for graviditet, men alder er fortsatt den viktigste faktoren (6, 7). En stor dansk studie finner ingen sammenheng mellom aluminium i barnevaksiner og sykdom – til tross for politisk press om tilbaketrekking (8, 9). Interessekonflikter i USAs vaksinekomiteer har falt kraftig de siste 25 årene (10, 11). Genterapi med CRISPR gir håp for hjernesykdommer, men det er ikke uten utfordringer (12). Svenske registerdata viser at ADHD-medisin kan redusere risikoen for uheldige utfall som rus, kriminalitet og selvmordsatferd (13). Foreldre tilbys å sende inn barnas melketenner til private selskaper for å utvinne og lagre stamceller – men lovnadene er langt foran forskningen (14). Se hele litteraturlista her: https://tidsskriftet.no/2025/08/podkast/redaktorens-hjorne-91-poteter-og-type-2-diabetes-crispr-stamcellelagring-fra-melketenner Tilbakemeldinger kan sendes til stetoskopet@tidsskriftet.no.          Stetoskopet produseres av Helena Heimer Rognstad, Are Brean, Ragnhild Ørstavik og Julie Didriksen ved Tidsskrift for Den norske legeforening. Ansvarlig redaktør er Are Brean.          Jingle og lydteknikk: Håkon Braaten / Moderne media  Coverillustrasjon: Stephen Lee  See omnystudio.com/listener for privacy information.

Can CRISPR help build a unified platform for biological discovery?Dr Kaivalya Shevade from the Laboratory for Genomics Research (UCSF) is developing new CRISPR-based screening methods to map gene networks, understand drug resistance, and track neuronal activity in disease. The research team's innovations, including the CAT-ATAC assay and the Plexus machine learning model, show how combining biology with computation could accelerate the search for new treatments.Read the original research: doi.org/10.1101/2025.02.11.637716

El plástico usado en botellas y envases (PET) tarda siglos en degradarse y contamina mares, ríos y suelos. Pero, ¿y si unas bacterias pudieran comérselo? Manuel Ferrer, nuestro invitado en Hablando con Científicos, es uno de los investigadores del CSIC que, junto a colegas del Barcelona Supercomputing Center, ha logrado enseñar a la bacteria E. coli, muy común en los laboratorios, a degradar plástico. La clave es GenRewire, una técnica que combina inteligencia artificial, supercomputadores y CRISPR, el famoso “corta y pega” genético. En lugar de añadir genes de otras especies, los científicos reprogramaron las propias proteínas de E. coli para que aprendiera a romper el PET. ¿El resultado? La bacteria consiguió deshacer nanopartículas de plástico y transformarlas en compuestos que incluso pueden reutilizarse. Por ahora es solo una prueba de concepto, pero abre un camino fascinante: crear microbios “recicladores” capaces de convertir montañas de residuos en nuevos recursos.

El plástico usado en botellas y envases (PET) tarda siglos en degradarse y contamina mares, ríos y suelos. Pero, ¿y si unas bacterias pudieran comérselo? Manuel Ferrer, nuestro invitado en Hablando con Científicos, es uno de los investigadores del CSIC que, junto a colegas del Barcelona Supercomputing Center, ha logrado enseñar a la bacteria E. coli, muy común en los laboratorios, a degradar plástico. La clave es GenRewire, una técnica que combina inteligencia artificial, supercomputadores y CRISPR, el famoso “corta y pega” genético. En lugar de añadir genes de otras especies, los científicos reprogramaron las propias proteínas de E. coli para que aprendiera a romper el PET. ¿El resultado? La bacteria consiguió deshacer nanopartículas de plástico y transformarlas en compuestos que incluso pueden reutilizarse. Por ahora es solo una prueba de concepto, pero abre un camino fascinante: crear microbios “recicladores” capaces de convertir montañas de residuos en nuevos recursos.

On this episode of The Agronomists, host Lyndsey Smith is joined by guests Dr. Liping Wang from the University of Guelph and Chris Manchur from the Canola Council of Canada to discuss RNAi technology and CRISPR technology, how they work, and how these plant breeding techniques could impact cropping decisions in the future. From what... Read More

In this episode of Ag Tech Talk by AgriBusiness Global, we're joined by Prof. Michael Strano, Professor of Chemical Engineering at MIT and Co-Lead Principal Investigator at the Disruptive & Sustainable Technologies for Agricultural Precision (DiSTAP) interdisciplinary research group at the Singapore-MIT Alliance for Research & Technology (SMART), MIT's research enterprise in Singapore. Strano shared how his team is pioneering real-time, non-invasive plant monitoring technologies that tap directly into the chemical “nervous system” of crops. Strano explains how tools like nanosensors, AI, and controlled environment systems are reshaping how we understand and optimize plant growth. From hormone-based crop diagnostics to nanotechnology-powered fertilizers and CRISPR delivery, he explores the innovations needed to close the gap between food security and sustainability—and what it will take to bring these tools to farms around the world.

If DNA is just a string of letters, could AI learn to read it … or even write it? Bioengineering researcher Eric Nguyen reveals how AI has upended the rules of biology, potentially creating a future where disease is cured with personalized medicine, extinct species are resurrected (Jurassic Park, anyone?) and microbes designed for Mars make interplanetary life possible. Learn more about how the world's first AI-designed CRISPR model successfully edited genes — and what it means for our understanding of life itself.For a chance to give your own TED Talk, fill out the Idea Search Application: ted.com/ideasearch.Interested in learning more about upcoming TED events? Follow these links:TEDNext: ted.com/futureyouTEDSports: ted.com/sportsTEDAI Vienna: ted.com/ai-viennaTEDAI San Francisco: ted.com/ai-sf Hosted on Acast. See acast.com/privacy for more information.

For UC Berkeley's Jennifer Doudna, the revolutionary discovery of CRISPR-Cas9 gene editing began 15 years ago with a meeting at the campus's Free Speech Movement Cafe. “This is a quintessential story about Berkeley,” begins Doudna, a professor of molecular and cell biology and of chemistry, in a lecture she gave on campus in April. “The research that I'll talk about today wouldn't have happened … if I had been working anywhere else. And that's because we have a really collaborative environment on our campus.”At the cafe, Doudna listened while a Berkeley colleague described a possible adaptive immune system in bacteria that helps them fight off viral infection. Doudna's lab went on to research the molecules involved, discovering a pathway that allows bacteria to "learn" about viruses, store the information and use it for protection.The scientists realized this same system could be used to trigger DNA repair in plant, animal and human cells, effectively allowing them to "rewrite the code of life." The seminal paper on CRISPR was published in 2012 by Doudna and her key collaborator, French microbiologist Emmanuelle Charpentier. The pair went on to win the Nobel Prize in Chemistry in 2020.In this Berkeley Talks episode, Doudna discusses how CRISPR can be used to correct disease-causing genetic mutations, the impact that it's already having on people's lives and where she sees the technology going in the future. “We're in an era of programmable genome editing,” she says. “It's really exciting to see all the possible applications of this. We know that it can be safe and effective to treat and even to potentially cure human disease, and we need to continue to advance the technology so that it can be deployed more widely.”Not only will that require continual activity on the science and technology front, she adds, but also in developing appropriate guidelines and regulations to ensure that CRISPR's applications move forward responsibly. Doudna's talk took place on April 4 as part of Brilliance of Berkeley, a course offered every spring by the College of Letters and Science that celebrates the campus's exceptional faculty and their accomplishments. Each week, students listen to two guest lectures by top Berkeley scholars from an array of fields, followed by a Q&A. Watch the video on the Brilliance of Berkeley YouTube page. Listen to the episode and read the transcript on UC Berkeley News (news.berkeley.edu/podcasts/berkeley-talks).Music by HoliznaCC0.Photo by Glenn Ramit/IGI. Hosted on Acast. See acast.com/privacy for more information.

CRISPR technology has revolutionised biological research, and for the first time it's out of the lab and into the NHS, as NICE has approved its use as cost effective. Kenneth Charles, senior lecturer in haematology at the University of the West Indies explains how the treatment works, and what concerns he has about it's implementation. Also this week, a new investigation on bmj.com has looked at a number of British companies who are offering to collect children's teeth for stem cell extraction and storage. Freelance investigative journalist Emma Wilkinson explains the "outrageous" claims she found them making. Finally - we're finishing with the football. Team GB had a strong showing this year -  our over 25 men's team brought the trophy home, and our womans team competed for the first time To explain more about the medical world cup we're joined by Minnan Al-Khafaji, captain of the women's team, and Jamie Thoroughgood, captain of the men's team.   Read more. Banking baby teeth: companies may be misleading parents with “outrageous claims” CRISPR therapy for sickle cell disease Follow the British Medical Football Team on instagram

Joined by the amazing Heidi (Unfiltered Rise) to discuss the tangled web of CRISPR and bio-engineered "recreational" drugs. We dive deep into the co-opting of nature, ancient rituals, and spiritual attacks.  She shares a personal story of a loved one who suffered injury from one of these substances. What are the long-term health consequences? Are government-approved grow facilities regulated? Do substance abuse facilities take patients who suffer harmful effects from these altered natural substances? We discuss cognitive behavioral therapy and much more! Follow Heidi at www.unfilteredrisepodcast.com IG @unfilteredrise_podcast  X @UnfilteredRise On Patreon and Spotify   #CRISPR #co-opting #recreationaldrugs #healthconsequences #regulation #governance #safety

The fuss over Sydney Sweeney's jeans/genes ad, and there are those who accused her of "normalizing eugenics," misses an important point: we are already doing another round of eugenics. It's just that this round is about the Haves having access to surrogates, IVF, CRISPR, and other genetic assistance while the Have Nots have plummeting fertility rates and no longterm care options when they have children with health problems. Jessa and Nico talk about the history of eugenics, why it was a leftist cause for so long, and what a baby with a $5 million miracle cure says about the future of humanity. Shownotes and references: http://theculturewedeserve.substack.com

[01:00:44] EU Push for WarOpening monologue frames EU leaders' Oval Office visit as another step toward World War III, warning of elites driving conflict. [01:02:13] Chemo Costs & CorruptionKansas woman forced to sell baked goods for $10,000/month chemo illustrates Big Pharma greed and insurance industry corruption, with added discussion of chemo's brain damage. [01:20:33] Soros & Ukraine RevolutionsClips of George Soros admitting to funding Ukraine's revolution reinforce claims of Western-engineered regime change and manufactured conflict. [01:23:02] COVID Propaganda MachineActors and government PSAs compared to “I play a doctor on TV,” exposing taxpayer-funded psy-ops that pushed vaccines and lockdowns. [01:27:00] NATO & Endless WarsCriticism of NATO as an entangling alliance meant to drag the U.S. into European wars, with sanctions framed as acts of war. [01:42:00] Culture Wars: Tradwives & FuentesAnalysis of “tradwife” influencers like Lauren Southern and Nick Fuentes, accusing them of cosplaying tradition and discouraging real families, seen as controlled opposition undermining Western civilization. [02:25:03] Milo & the Right-Wing CircusDiscussion of Milo Yiannopoulos as an unstable provocateur, linked to Alex Jones, with comparisons to Laura Loomer; highlights the grifter culture. [02:25:44] AI as Modern IdolatryHealth Impact article sparks a segment framing AI as today's “talking idols,” reflecting human emptiness rather than true intelligence. [02:45:30] CRISPR & AI GeneticsConcerns raised that CRISPR gene editing is more like a chainsaw than a scalpel, with elites now turning to AI to “clean up” dangerous genetic manipulation. [02:49:19] De-Banking & StablecoinsDiscussion of Bank of America walking back “debanking” rules against religious groups, but warning that stablecoins are a Trojan horse for CBDCs and government financial control. [03:11:01] Trump Tariffs & Food CostsNew tariffs on Brazil, Switzerland, and Mexico predicted to raise prices on coffee, chocolate, olive oil, and groceries. Large corporations can absorb costs temporarily, but small businesses and consumers will feel the squeeze. [03:29:48] Israeli Official & Sex CrimesCoverage of an Israeli official caught in a Nevada sex crime sting but quietly returned to Israel, sparking discussion of influence, Epstein networks, and government protection of predators. [03:44:05] Pornography, AI & Spiritual WarAnalysis of how pornography addiction undermines churches, worsened by AI chatbots and virtual companions that manipulate users — framed as a spiritual battle for minds and families. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[01:00:44] EU Push for WarOpening monologue frames EU leaders' Oval Office visit as another step toward World War III, warning of elites driving conflict. [01:02:13] Chemo Costs & CorruptionKansas woman forced to sell baked goods for $10,000/month chemo illustrates Big Pharma greed and insurance industry corruption, with added discussion of chemo's brain damage. [01:20:33] Soros & Ukraine RevolutionsClips of George Soros admitting to funding Ukraine's revolution reinforce claims of Western-engineered regime change and manufactured conflict. [01:23:02] COVID Propaganda MachineActors and government PSAs compared to “I play a doctor on TV,” exposing taxpayer-funded psy-ops that pushed vaccines and lockdowns. [01:27:00] NATO & Endless WarsCriticism of NATO as an entangling alliance meant to drag the U.S. into European wars, with sanctions framed as acts of war. [01:42:00] Culture Wars: Tradwives & FuentesAnalysis of “tradwife” influencers like Lauren Southern and Nick Fuentes, accusing them of cosplaying tradition and discouraging real families, seen as controlled opposition undermining Western civilization. [02:25:03] Milo & the Right-Wing CircusDiscussion of Milo Yiannopoulos as an unstable provocateur, linked to Alex Jones, with comparisons to Laura Loomer; highlights the grifter culture. [02:25:44] AI as Modern IdolatryHealth Impact article sparks a segment framing AI as today's “talking idols,” reflecting human emptiness rather than true intelligence. [02:45:30] CRISPR & AI GeneticsConcerns raised that CRISPR gene editing is more like a chainsaw than a scalpel, with elites now turning to AI to “clean up” dangerous genetic manipulation. [02:49:19] De-Banking & StablecoinsDiscussion of Bank of America walking back “debanking” rules against religious groups, but warning that stablecoins are a Trojan horse for CBDCs and government financial control. [03:11:01] Trump Tariffs & Food CostsNew tariffs on Brazil, Switzerland, and Mexico predicted to raise prices on coffee, chocolate, olive oil, and groceries. Large corporations can absorb costs temporarily, but small businesses and consumers will feel the squeeze. [03:29:48] Israeli Official & Sex CrimesCoverage of an Israeli official caught in a Nevada sex crime sting but quietly returned to Israel, sparking discussion of influence, Epstein networks, and government protection of predators. [03:44:05] Pornography, AI & Spiritual WarAnalysis of how pornography addiction undermines churches, worsened by AI chatbots and virtual companions that manipulate users — framed as a spiritual battle for minds and families. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

On this episode of The Innovation Storytellers Show, I sit down with Dr. William Pao, physician scientist, former Chief Development Officer at Pfizer, and author of Breakthrough – The Quest for Life-Changing Medicines. His journey into medicine began with the loss of his father to cancer when he was just 13 years old, a moment that shaped his life's mission to develop treatments that change outcomes for patients everywhere. We explore the extraordinary, and often invisible, process of medical innovation. Dr. Pao takes us behind the scenes of eight real-world breakthroughs, revealing the persistence, failures, and unexpected turns that happen long before a drug reaches the market. He shares the story of a 15-year effort to create an HIV capsid inhibitor now given just twice a year, and how a combination of basic science curiosity and problem-solving under pressure turned a limitation into a breakthrough. We dive into the development of CRISPR-based therapies for sickle cell disease and thalassemia, a century-long scientific journey that required insights from genetics, epidemiology, and bioengineering before it could cure patients. Throughout our conversation, Dr. Pao brings these stories to life with the human elements that make them possible. We talk about the “killer experiment” mindset that helps teams decide whether to keep going or shut a project down, the value of institutional memory, and why innovation in medicine requires a rare mix of biological insight, clinical understanding, and technological advancement. We also explore the emotional side of the work, how innovators cope with fatigue, navigate internal resistance, and make hard calls when decades of work are on the line. Whether you are developing life-saving drugs or leading innovation in a completely different field, you will find practical lessons here. Dr. Pao's experiences show how to work through uncertainty, keep an open mind to ideas from outside your domain, and maintain the discipline to make good decisions even when the stakes are high.  

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

My guest is Dr. Sergiu Pașca, MD, professor of psychiatry and behavioral sciences at Stanford University. We discuss the biology and genetics of autism, why autism diagnoses are increasing and recent progress in using stem cells to understand and treat profound autism and other brain disorders. Dr. Pașca explains “organoids and assembloids”—human stem cell–derived tools he pioneered to study, treat and cure complex brain diseases. We also discuss ethical and safety issues with using gene editing and stem cells in humans. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman Helix: https://helixsleep.com/huberman BetterHelp: https://betterhelp.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00) Sergiu Pașca (02:08) Autism Spectrum Disorder, Incidence, Genetics (07:16) Is Autism More Common in Males? (09:35) Sponsors: David & Helix Sleep (11:56) Eye Contact in Babies, Fever; Proposed Causes of Autism; Genes (18:48) Genetic or Idiopathic Autism Diagnoses, Timothy Syndrome (21:37) Rise in Autism Diagnoses (26:46) Cause, Correlation & Neurological Disease; Schizophrenia, Do Vaccines Cause Autism? (31:34) Global Increase in Autism; Gene Therapy, CRISPR, Follistatin (41:05) Sponsors: AG1 & BetterHelp (43:41) Stem Cells, Ethics, Yamanaka Factors, Human Stem Cell Models (52:03) Umbilical Stem Cells; Stem Cell Injections & Dangers, Autistic Kids (59:30) Organoids, Modeling Brain Development, Intrinsic Development Timer (1:12:22) Assembloids, Brain Cell Migration & Circuit Formation, Self-Organization (1:21:22) Four-Part Assembloid, Sensory Assembloid, Pain Conditions (1:25:45) Sponsor: Function (1:27:33) Future Medical Therapies, Cell Banking, Immortalize Tissues, Rejuvenate Cells (1:34:56) Assembloids & Ethics, Importance of Nomenclature, Science Collaboration & Self-Correction (1:45:38) Cell Transplantation & Ethics, Timing (1:55:05) Genetic Testing for Parents, Genetic Penetrance (2:02:36) Assembloids, Timothy Syndrome, Epilepsy, Schizophrenia, Dystonia (2:14:30) Scientific Career, Walking, Art, Medical School (2:20:44) Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

About this episode:  Sickle cell disease affects an estimated 100,000 people in the United States. Recent advancements in gene therapies and medicines like hydroxyurea are diminishing extreme pain, reducing strokes, and extending survival times for those afflicted by the disease. In this episode: leading sickle cell disease expert Dr. Mark Gladwin explains how revolutionary new treatments work and discusses the challenges to access to life-saving care. Guest: Dr. Mark Gladwin is a physician-scientist and the Dean of the University of Maryland School of Medicine and Vice President for Medical Affairs at the University of Maryland, Baltimore. His research focuses include sickle cell disease and hypertension. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle—CNBC Gene Therapy: What You Need to Know—Sickle Cell Disease Association of American No More Pain: Breakthrough Sickle Cell Treatment from Johns Hopkins Offers Curative Potential—Johns Hopkins School of Medicine Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

I know exactly what you're thinking: What happened in Israel regarding the five perfect red heifers? Pastor Gene Pensiero Find audio, video, and text of hundreds of other prophecy updates at: https://calvaryhanford.com/prophecy Read along with us at https://calvaryhanford.substack.com Follow us on YouTube at https://youtube.com/calvaryhanford — In this prophecy update, we dive deep into one of […]

ORIGINAL AIR DATE: AUG 2, 2015An amazing conversation from a decade ago with the amazing Dr. Thomas Horn, on the subject of Transhumanism.Here is the documentary Tom refers to: https://www.youtube.com/watch?v=8QG1EgkpJX4Sheila's content is viewer supported.SHEILA WEBSITE: https://sheilazilinsky.comHOW TO GIVE: https://sheilazilinsky.com/givingVenmo https://venmo.com/u/SheilaZilinskyCash app https://cash.app/$SheilaZilinskyZelle sheila@sheilazilinsky.comPayPal https://www.paypal.com/paypalme/sheilazilinskyPatreon https://www.patreon.com/sheilazilinskyHOW TO LISTEN:BRAND NEW YOUTUBE CHANNEL https://www.youtube.com/@realsheilazRumble: https://rumble.com/user/RealSheilaZPodcast: https://www.podomatic.com/podcasts/sheilazilinskyApple Podcast: https://podcasts.apple.com/ca/podcast/the-sheila-zilinsky-show/id960689559FOLLOW SHEILA:Telegram: https://t.me/realsheilazTwitter: https://twitter.com/RealSheilaZFacebook: https://www.facebook.com/realSheilaZInstagram: https://www.instagram.com/sheilazilinskySubstack: https://sheilazilinsky.substack.com

Targeting small atomic groups around genes shows promise in the treatment of genetic blood diseases.

What happens when creating a child becomes a consumer choice? In this provocative episode of Brave New Us, research associate at the Heritage Foundation Emma Waters joins host Samantha Stephenson to break down the rising trend of embryo screening, designer genetics, and artificial wombs. From Elon Musk's child-maxxing to CRISPR enhancements and Build-a-Baby startups like Nucleus Genomics and Orchid, we explore how reproductive technologies are reshaping what it means to become a parent—and what's at stake for the children created through these tools.If you've ever asked yourself: • Is embryo selection a form of modern eugenics? • Can we separate desire from design in the future of family building? • Are children becoming products instead of persons? • What's the difference between healing and enhancement in genetic medicine?Topics Covered:Why "have healthy babies" is a deceptive marketing sloganThe ethics of picking embryos based on IQ, personality, or sexThe rise of child-maxxing among elites like Elon MuskWhy "designer babies" deepen inequality and threaten parent-child loveWhat three-parent embryos and artificial gametes mean for the future of familyThe philosophy behind eugenics—and why it's rebranded, not goneWhen CRISPR gene editing might cross the line from healing to hubrisWhy strong families—not just birthrates—should be the goal of pronatalismMentioned in the EpisodeEmma Waters' work on pronatalism and reproductive ethicsConnect with Emma on X (Twitter)New Atlantis article: Stop Hacking HumansPublic Discourse article: The Pronatalism and Silicon ValleyLeave a Review + Share the Show If this conversation made you think differently about the future of family, science, and ethics, please:Rate and review Brave New Us on Apple Podcasts or SpotifyShare this episode with a friend or on social mediaKeep the conversation going at bravenewus.substack.com

A Chinese scientist, He Jiankui, made a shocking announcement to the world in 2018: He had secretly engineered the birth of the first gene-edited babies. The birth of the twins was seen as reckless and unethical by the scientific community. That's because, among other things, the CRISPR gene-editing technique Jiankui used was so new. NPR science correspondent Rob Stein has been following the controversial world of gene-editing and human reproduction, including some companies' recent quests to push gene-editing technology forward.Read more of Rob Stein's reporting on the topic here.Interested in more science news? Let us know at shortwave@npr.org. Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

היעד הבא של נאס"א: כור גרעיני על הירח עד 2030 / מדענים הצליחו להשתמש בטכנולוגיית העריכה הגנטית CRISPR כדי להסיר את הכרומוזום העודף שגורם לתסמונת דאון / כשאנו רואים מישהו חולה, המערכת החיסונית שלנו נכנסת לכוננות / חוקרים סינים הצליחו "להשתיל" מוח של קוף על מחשב, בעזרת בינה מלאכותיתמגיש: אורי גוטליב, עורכת: אלכס לויקר, מפיקה: תמר בנימין, טכנאי: תום חלדSee omnystudio.com/listener for privacy information.

Dr. Hoffman continues his conversation with Zen Honeycutt, founder and executive director of Moms Across America and author of “Unstoppable: Transforming Sickness and Struggle into Triumph, Empowerment and a Celebration of Community.” 

Zen Honeycutt, founder and executive director of Moms Across America and author of “Unstoppable: Transforming Sickness and Struggle into Triumph, Empowerment and a Celebration of Community,” details the origins and mission of the nonprofit organization aimed at transforming the food supply and improving health by reducing chemicals in food, water, and air. Highlighting the impact of grassroots activism, Honeycutt illustrates how the organization's initiatives have driven significant awareness and policy changes, including advances in organic food consumption and labeling. She also touches on the challenges posed by government and corporate influences, advocating for policies that put children's health and safety first. Honeycutt emphasizes the importance of individual actions and community involvement in creating a healthier future.

* Of Pangolins and Protection: Fred and Ryan review the latest Creation Magazine, starting with the pangolin! Its an armored, anteater-like creature with keratin scales and unique defensive design. Evolutionists once linked it to armadillos, but genetic studies disproved the connection, forcing an appeal to convergent evolution—a recurring "rescue device" for failing Darwinian models. * Shark Skin and Airplanes: From ocean to air, shark skin's ridged structure reduces drag. Engineers have reverse-engineered this feature for airplane coatings and banned swimsuits. Like past guest Dr. Michael Egnor noted, reverse engineering proves intentional design. * A Forest from a Warmer Past: Global warming headlines falter as ancient warm-climate forests are discovered under melting snow in Wyoming.  * Dawkins vs. Dawkins: Irony strikes as atheist icon Richard Dawkins clashes with the Freedom From Religion Foundation over gender ideology. Dawkins is now censored for insisting humans can't change biological sex. As Romans 1 says, suppressing truth leads to folly. *  Life on Bennu? Not So Fast: NASA's return samples from asteroid Bennu contain racemic amino acids—both left and right-handed—suggesting death, not life. Fred and Ryan highlight the missed opportunity by CMI to support the Hydroplate Theory, which better explains why Earth-like materials (like serpentinite) are found in space. * Dire Wolves and DNA: A biotech firm claims to have "de-extincted" the Ice Age dire wolf using CRISPR and gray wolf DNA. But critics argue it's just a genetically engineered look-alike. The ethics—and science fiction parallels—raise valid concerns about modern tinkering with life. * Ant Eyes and Imaging Breakthroughs: Desert ants' compound eyes detect polarized light to navigate featureless landscapes. Chinese scientists copied this tech to enhance imaging—enabling detection of cancer cells without staining. Once again, man learns from the Master Engineer.

* Of Pangolins and Protection: Fred and Ryan review the latest Creation Magazine, starting with the pangolin! Its an armored, anteater-like creature with keratin scales and unique defensive design. Evolutionists once linked it to armadillos, but genetic studies disproved the connection, forcing an appeal to convergent evolution—a recurring "rescue device" for failing Darwinian models. * Shark Skin and Airplanes: From ocean to air, shark skin's ridged structure reduces drag. Engineers have reverse-engineered this feature for airplane coatings and banned swimsuits. Like past guest Dr. Michael Egnor noted, reverse engineering proves intentional design. * A Forest from a Warmer Past: Global warming headlines falter as ancient warm-climate forests are discovered under melting snow in Wyoming.  * Dawkins vs. Dawkins: Irony strikes as atheist icon Richard Dawkins clashes with the Freedom From Religion Foundation over gender ideology. Dawkins is now censored for insisting humans can't change biological sex. As Romans 1 says, suppressing truth leads to folly. *  Life on Bennu? Not So Fast: NASA's return samples from asteroid Bennu contain racemic amino acids—both left and right-handed—suggesting death, not life. Fred and Ryan highlight the missed opportunity by CMI to support the Hydroplate Theory, which better explains why Earth-like materials (like serpentinite) are found in space. * Dire Wolves and DNA: A biotech firm claims to have "de-extincted" the Ice Age dire wolf using CRISPR and gray wolf DNA. But critics argue it's just a genetically engineered look-alike. The ethics—and science fiction parallels—raise valid concerns about modern tinkering with life. * Ant Eyes and Imaging Breakthroughs: Desert ants' compound eyes detect polarized light to navigate featureless landscapes. Chinese scientists copied this tech to enhance imaging—enabling detection of cancer cells without staining. Once again, man learns from the Master Engineer.

When we think about gene editing, the conversation often feels trapped between scientific journals and ethical debates too complex for public forums. In this episode, I spoke with Neal Baer, a rare voice who bridges both worlds. Known to many as an award-winning television showrunner for series like ER, Law & Order SVU, and Designated Survivor, Neal is also a Harvard-trained physician and co-director of the Media, Medicine, and Health program at Harvard Medical School. His latest project brings all of that experience together in a new collection of essays that explores the promise and peril of CRISPR gene-editing technology. Neal takes us on a journey that begins with his time as a medical resident treating a young sickle cell patient, and leads to a much broader conversation about science, ethics, and storytelling. We discuss how CRISPR is already being used to cure diseases like sickle cell, and how companies are now exploring gene edits that promise permanent reductions in cholesterol. But the real power of this discussion is not just in what CRISPR can do, but in what we still don't fully understand about its long-term impact. The conversation moves into difficult territory—unintended mutations, germline editing, the risk of pathologizing human diversity, and the slippery slope of “enhancement” where only those with access can benefit. Neal raises critical questions about the social cost of deciding which conditions should be “fixed” and who gets to make that call. We also dive into the lack of political and regulatory oversight, and why a global framework, not just scientific advancement, is urgently needed. This episode offers a powerful reminder that the future of CRISPR shouldn't be left solely to researchers or startups. It demands wide engagement, from classrooms to policymaking, and inclusive voices that challenge how we define progress. How should we decide what counts as improvement when the very definition of being human is at stake?

Broadcasting live from the heart of Baltic, South Dakota, this episode of What's On Your Mind hits the airwaves from the annual PhD Field Day, hosted by the Hefty Seed Company. Join Scott Hennen and Dean Wysocki as they meet farmers, industry leaders, and meteorologists to talk cutting-edge agtech, long-range weather forecasting, biologicals, education, and the now-infamous “great jeans” ad controversy that has social media buzzing. This is ag radio at its finest—informative, unfiltered, and occasionally hilariously off-track (mini donuts, anyone?). Whether you farm or just love good radio, this episode has something for you. ⏱️ Standout Moments & Timestamps: [00:50] – “Live from Baltic!” — Broadcasting setup and Field Day preview. [02:07] – F-35 crash and viral fighter jet video from Spain

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Michael S. Okun, MD, FAAN, who served as the guest editor of the August 2025 Movement Disorders issue. They provide a preview of the issue, which publishes on August 1, 2025. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Okun is the director at Norman Fixel Institute for Neurological Diseases and distinguished professor of neurology at University of Florida in Gainesville, Florida. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @MichaelOkun Full episode transcript available here: Dr Jones: Our ability to move through the world is one of the essential functions of our nervous system. Gross movements like walking ranging down to fine movements with our eyes and our hands, our ability to create and coordinate movement is something many of us take for granted. So what do we do when those movements stop working as we intend? Today I have the opportunity to speak with one of the world's leading experts on movement disorders, Dr Michael Okun, about the latest issue of Continuum on Movement Disorders. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyle Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Michael Okun, who is Continuum's guest editor for our latest issue on movement disorders. Dr Okun is the Adelaide Lackner Distinguished Professor of Neurology at the University of Florida in Gainesville, where he's also the director of the Norman Fixel Institute for Neurological Diseases. Dr Okun, welcome, and thank you for joining us today. Why don't you introduce yourselves to our listeners?  Dr Okun: It's great to be here today. And I'm a neurologist. Everybody who knows me knows I'm pretty simple. I believe the patient's the sun and we should always orbit around the person with disease, and so that's how I look at my practice. And I know we always participate in a lot of research, and I've got a research lab and all those things. But to me, it's always the patients and the families first. So, it'll be great to have that discussion today.  Dr Jones: Yeah, thank you for that, Dr Oaken. Obviously, movement disorders is a huge part of our field of neurology. There are many highly prevalent conditions that fit into this category that most of our listeners will be familiar with: idiopathic Parkinson's disease, essential tremor, tic disorders and so on. And having worked with trainees for a long time, it's one of the areas that I see a lot of trainees gravitate to movement disorders. And I think it's in part because of the prevalence; I think it's in part because of the diversity of the specialty with treatment options and DBS and Botox. But it's also the centrality of the neurologic exam, right? That's- the clinical examination of the patient is so fundamental. And we'll cover a lot of topics today with some questions that I have for you about biomarkers and new developments in the field. But is that your sense too, that people are drawn to just the old-fashioned, essential focus on the neurologic encounter and the neurologic exam? Dr Okun: I believe that is one of the draws to the field of movement. I think that you have neurologists from all over the world that are really interested and fascinated with what things look like. And when you see something that's a little bit, you know, off the normal road or off the normal beaten path… and we are always curious. And so, I got into movement disorders, I think, accidentally; I think even as a child, I was looking at people who had abnormal movements and tremors and I was very fascinated as to why those things happened and what's going on in the brain. And, you know, what are the symptoms and the signs. And then later on, even as my own career developed, that black bag was so great as a neurologist. I mean, it makes us so much more powerful than any of the other clinicians---at least in my biased opinion---out on the wards and out in the clinic. And, you know, knowing the signs and the symptoms, knowing how to do a neurological examination and really walking through the phenomenology, what people look like, you know, which is different than the geno- you know, the genotypes, what the genes are. What people look like is so much more important as clinicians. And so, I think that movement disorders is just the specialty for that, at least in my opinion. Dr Jones: And it helps bring it back to the patient. And that's something that I saw coming through the articles in this issue. And let's get right to it. You've had a chance to review all these articles on all these different topics across the entire field of movement disorders. As you look at that survey of the field, Dr Okun, what do you think is the most exciting recent development for patients with movement disorders?  Dr Okun: I think that when you look across all of the different specialties, what you're seeing is a shift. And the shift is that, you know, a lot of people used to talk in our generation about neurology being one of these “diagnose and adios” specialties. You make the diagnosis and there's nothing that you can do, you know, about these diseases. And boy, that has changed. I mean, we have really blown it out of the water. And when you look at the topics and what people are writing about now and the Continuum issue, and we compare that the last several Continuum issues on movement disorders, we just keep accumulating a knowledge base about what these things look like and how we can treat them. And when we start thinking about, you know, all of the emergence of the autoimmune disorders and identifying the right one and getting something that's quite treatable. Back in my day, and in your day, Lyle, we saw these things and we didn't know what they were. And now we have antibodies, now we can identify them, we can pin them down, and we can treat many of them and really change people's lives. And so, I'm really impressed at what I see in changes in identification of autoimmune disorders, of channelopathies and some of the more rare things, but I'm also impressed with just the fundamental principles of how we're teaching people to be better clinicians in diseases like Parkinson's, Huntington's, ataxia, and Tourette. And so, my enthusiasm for this issue of Continuum is both on, you know, the cutting edge of what we're seeing based on the identification on our exams, what we can do for these people, but also the emergence of how we're shifting and providing much better care across a continuum for folks with basal ganglia diseases. Dr Jones: Yeah, I appreciate that perspective, Dr Okun. One of the common themes that I saw in the issue was with these new developments, right, when you have new tools like new diagnostic biomarker tools, is the question of if and when and how to integrate those into daily clinical practice, right? So, we've had imaging biomarkers for a while, DAT scans, etc. For patients with idiopathic Parkinson disease, one of the things that I hear a lot of discussion and controversy about are the seed amplification assays as diagnostic biomarkers. What can you tell us about those? Are those ready for routine clinical use yet?  Dr Okun: I think the main bottom-line point for folks that are out there trying to practice neurology, either in general clinics or even in specialty clinics, is to know that there is this movement toward, can we biologically classify a disease? One of the things that has, you know, really accelerated that effort has been the development of these seed amplification assays, which---in short for people who are listening---are basically, we “shake and bake” these things. You know? We shake them for like 20 hours and we use these prionlike proteins, and we learn from diseases like prion disease how to kind of tag these things and then see, do they have degenerative properties? And in the case of Parkinson's disease, we're able to do this with synuclein. That is the idea of a seed amplification assay. We're able to use this to see, hey, is there synuclein present or not in this sample? And people are looking at things like cerebrospinal fluid, they're looking at things like blood and saliva, and they're finding it. The challenge here is that, remember- and one of the things that's great about this issue of Continuum is, remember, there are a whole bunch of different synucleinopathies. So, Dr Jones, it isn't just Parkinson's disease. So, you've got Parkinson's disease, you've got Lewy body, you know, and dementia with Lewy bodies. You've got, you know, multiple system atrophy is within that synucleinopathy, you know, group primary autonomic failure… so not just Parkinson's disease. And so, I think we have to tap the brakes as clinicians and just say, we are where we are. We are moving in that direction. And remember that a seed amplification assay gives you some information, but it doesn't give you all the information. It doesn't forgive you looking at a person over time, examining them in your clinic, seeing how they progress, seeing their response to dopamine- and by the way, several of these genes that are associated with Parkinson; and there's, you know, less than 20% of Parkinson is genetic, but several of these genes, in a solid third---and in some cases, in some series, even more---miss the synuclein assay, misses, you know, the presence of a disease like Parkinson's disease. And so, we have to be careful in how we interpret it. And I think we're more likely to see over time a gemish: we're going to smush together all this information. We're going to get better with MRIs. And so, we're actually doing much better with MRIs and AI-based intelligence. We've got DAT scans, we've got synuclein assays. But more than anything, everybody listening out there, you can still examine the person and examine them over time and see how they do over time and see how they do with dopamine. And that is still a really, really solid way to do this. The synuclein assays are probably going to be ready for prime time more in choosing and enriching clinical trials populations first. And you know, we're probably 5, 10 years behind where Alzheimer's is right now. So, we'll get there at some point, but it's not going to be a silver bullet. I think we're looking at these are going to be things that are going to be interpreted in the context for a clinician of our examination and in the context of where the field is and what you're trying to use the information for. Dr Jones: Thank you for that. And I think that's the general gestalt I got from the articles and what I hear from my colleagues. And I think we've seen this in other domains of neurology, right? We have the specificity and sensitivity issues with the biomarkers, but we also have the high prevalence of copathology, right? People can have multiple different neurodegenerative problems, and I think it gets back to that clinical context, like you said, following the patient longitudinally. That was a theme that came out in the idiopathic Parkinson disease article. And while we're on Parkinson disease, you know, the first description of that was what, more than two hundred years ago. And I think we're still thinking about the pathophysiology of that disorder. We understand risk factors, and I think many of our listeners would be familiar with those. But as far as the actual cause, you know, there's been discussion in recent years about, is there a role of the gut microbiome? Is this a prionopathic disorder? What's your take on all of that?  Dr Okun: Yeah, so it's a great question. It's a super-hot area right now of Parkinson. And I kind of take this, you know, apart in a couple of different ways. First of all, when we think about Parkinson disease, we have to think upstream. Like, what are the cause and causes? Okay? So, Parkinson is not one disease, okay? And even within the genes, there's a bunch of different genes that cause it. But then we have to look and say, well, if that's less than 20% depending on who's counting, then 80% don't have a single piece of DNA that's closely associated with this syndrome. And so, what are we missing with environment and other factors? We need to understand not what happens at the end of the process, not necessarily when synuclein is clumping- and by the way, there's a lot of synuclein in the brains normally, and there's a lot of Tau in people's brains who have Parkinson as well. We don't know what we don't know, Dr Jones. And so when we begin to think about this disease, we've got to look upstream. We've got to start to think, where do things really start? Okay? We've got to stop looking at it as probably a single disease or disorder, and it's a circuit disorder. And then as we begin to develop and follow people along that pathway and continuum, we're going to realize that it's not a one-size-fits-all equation when we're trying to look at Parkinson. By the way, for people listening, we only spend two to three cents out of every dollar on prevention. Wouldn't prevention be the best cure, right? Like, if we were thinking about this disease. And so that's something that we should be, you know, thinking about. And then the other is the Global Burden of Disease study. You know, when we wrote about this in a book called Ending Parkinson's Disease, it looked like Parkinson's was going to double by 2035. The new numbers tell us it's almost double to the level that we expected in 2035 in this last series of numbers. So, it's actually growing much faster. We have to ask why? Why is it growing faster? And then we have lots of folks, and even within these issues here within Continuum, people are beginning to talk about maybe these environmental things that might be blind spots. Is it starting in our nose? Is it starting in our gut? And then we get to the gut question. And the gut question is, if we look at the microbiomes of people with Parkinson, there does seem to be, in a group of folks with Parkinson, a Parkinson microbiome. Not in everyone, but if you look at it in composite, there seems to be some clues there. We see changes in Lactobacillus, we see some bacteria going up that are good, some bacteria going down, you know, that are bad. And we see flipping around, and that can change as we put people on probiotics and we try to do fecal microbiota transplantations- which, by the way, the data so far has not been positive in Parkinson's. Doesn't mean we might not get there at some point, but I think the main point here is that as we move into the AI generation, there are just millions and millions and millions of organisms within your gut. And it's going to take more than just our eyes and just our regular arithmetic. You and I probably know how to do arithmetic really well, but this is, like, going to be a much bigger problem for computers that are way smarter than our brains to start to look and say, well, we see the bacteria is up here. That's a good bacteria, that's a good thing or it's down with this bacteria or this phage or there's a relationship or proportion that's changing. And so, we're not quite there. And so, I always tell people---and you know, we talk about the sum in the issue---microbiomes aren't quite ready for prime time yet. And so be careful, because you could tweak the system and you might actually end up worse than before you started. So, we don't know what we don't know on this issue.  Dr Jones: And that's a great point. And one of the themes they're reading between the lines is, we will continue to work on understanding the bio-pathophysiology, but we can't wait until that day to start managing the risk factors and treating patients, which I think is a good point. And if we pivot to treatment here a little bit, you know, one of the exciting areas of movement disorders---and really neurology broadly, I think movement disorders has led the field in many ways---is bioelectronic therapy, or what one of my colleagues taught me is “electroceutical therapy”, which I think is a wonderful term. Dr Okun, when our listeners are hearing about the latest in deep brain stimulation in patients who have movement disorders, what should they know? What are the latest developments in that area with devices? Dr Okun: Yeah. So, they should know that things are moving rapidly in the field of putting electricity into the brain. And we're way past the era where we thought putting a little bit of electricity was snake oil. We know we can actually drive these circuits, and we know that many of these disorders---and actually, probably all of the disorders within this issue of Continuum---are all circuit disorders. And so, you can drive the circuit by modulating the circuit. And it's turned out to be quite robust with therapies like deep brain stimulation. Now, we're seeing uses of deep brain stimulation across multiple of these disorders now. So, for example, you may think of it in Parkinson's disease, but now we're also seeing people use it to help in cases where you need to palliate very severe and bothersome chorea and Huntington's disease, we're seeing it move along in Tourette syndrome. We of course have seen this for various hyperkinetic disorders and dystonias. And so, the main thing for clinicians to realize when dealing with neuromodulation is, take a deep breath because it can be overwhelming. We have a lot of different devices in the marketplace and no matter how many different devices we have in the marketplace, the most important thing is that we get the leads. You know, where we're stimulating into the right location. It's like real estate: location, location, location, whether you've got a lead that can steer left, right, up, down and do all of these things. Second, if you're feeling overwhelmed because there are so many devices and so many settings, especially as we put these leads in and they have all sorts of different, you know, nodes on them and you can steer this way and that way, you are not alone. Everybody is feeling that way now. And we're beginning to see AI solutions to that that are going to merge together with imaging, and then we're moving toward an era of, you know, should I say things like robotic programming, where it's going to be actually so complicated as we move forward that we're going to have to automate these systems. There's no way to get this and scale this for all of the locales within the United States, but within the entire world of people that need these types of devices and these therapies. And so, it's moving rapidly. It's overwhelming. The most important thing is choosing the right person. Okay? For this, with multidisciplinary teams, getting the lead in the right place. And then all these other little bells and whistles, they're like sculpting. So, if you think of a sculpture, you kind of get that sculpture almost there. You know, those little adds are helping to maybe make the eyes come out a little more or the facial expression a little bit better. There's little bits of sculpting. But if you're feeling overwhelmed by it, everybody is. And then also remember that we're starting to move towards some trials here that are in their early stages. And a lot of times when we start, we need more failures to get to our successes. So, we're seeing trials of people looking at, like, oligo therapies and protein therapies. We're seeing CRISPR gene therapies in the laboratory. And we should have a zero tolerance for errors with CRISPR, okay? we still have issues with CRISPR in the laboratory and which ones we apply it to and with animals. But it's still pretty exciting when we're starting to see some of these therapies move forward. We're going to see gene therapies, and then the other thing we're going to see are nano-therapies. And remember, smaller can be better. It can slip across the blood brain barrier, you have very good surface area-to-volume ratios, and we can uncage drugs by shining things like focused ultrasound beams or magnets or heat onto these particles to turn them on or off. And so, we're seeing a great change in the field there. And then also, I should mention: pumps are coming and they're here. We're getting pumps like we have for diabetes and neurology. It's very exciting. It's going to be overwhelming as everybody tries to learn how to do this. So again, if you're feeling overwhelmed, so am I. Okay? But you know, pumps underneath the skin for dopamine, pumps underneath the skin for apomorphine. And that may apply to other disorders and not just Parkinson as we move along, what we put into those therapies. So, we're seeing that age come forward. And then making lesions from outside the brain with focused ultrasound, we're starting to get better at that. Precision is less coming from outside the brain; complications are also less. And as we learn how to do that better, that also can provide more options for folks. So, a lot of things to read about in this issue of Continuum and a lot of really interesting and beyond, I would say, you know, the horizon as to where we're headed.  Dr Jones: Thank you for that. And it is a lot. It can be overwhelming, which I guess is maybe a good reason to read the issue, right? I think that's a great place to end and encourage our listeners to pick up the issue. And Dr Okun, I want to thank you for joining us today. Thank you for such a great discussion on movement disorders. I learned a lot. I'm sure our listeners will as well, given the importance of the topic, your leadership in the field over many years. I'm grateful that you have put this issue together. So, thank you. And you're a busy person. I don't know how we talked you into doing this, but I'm really glad that we did.  Dr Okun: Well, it's been my honor. And I just want to point out that the whole authorship panel that agreed to write these articles, they did all the work. I'm just a talking head here, you know, telling you what they did, but they're writing, and the people that are in the field are really, you know, leading and helping us to understand, and have really put it together in a way that's kind of helped us to be better clinicians and to impact more lives. So, I want to thank the group of authors, and thank you, Dr Jones. Dr Jones: Again, we've been speaking with Dr Michael Okun, guest editor of Continuum's most recent issue on movement disorders. Please check it out. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

In this essential episode of Parallax, Dr Ankur Kalra is joined by Dr Carolyn Ho, Professor of Medicine at Harvard Medical School and Medical Director of the Cardiovascular Genetics Program at Brigham and Women's Hospital, for a comprehensive discussion on how genetic testing is reshaping hypertrophic cardiomyopathy management. The conversation explores the VANISH HCM trial results, which showed that valsartan can slow disease progression in young, asymptomatic individuals with early sarcomeric HCM. Dr Ho discusses how this evidence influenced the 2024 HCM guidelines and created new opportunities for disease-modifying therapy before clinical symptoms appear. The episode also examines emerging gene-based therapeutics, from current adeno-associated virus approaches to future CRISPR technologies that could address the underlying genetic causes of HCM. Dr Ho addresses practical considerations for clinicians, including when to initiate genetic testing, how to manage family screening, and the promise of AI-assisted screening tools. The discussion highlights both current therapeutic options and the evolving landscape of precision medicine in inherited cardiovascular disease. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

The line between groundbreaking innovation and controversial ownership blurs when scientists begin creating life in laboratories. What happens when your invention isn't just a device or chemical formula, but a living, breathing, self-replicating organism that refuses to stay contained within traditional legal boundaries?Synthetic biology—the field where engineering meets genetics—has created a perfect storm for intellectual property law. Scientists can now design cells like software, program bacteria to clean oil spills, and edit genes with CRISPR technology. But who owns these inventions when they start reproducing themselves?From the landmark 1980 Chakrabarty decision that first allowed patents on genetically modified bacteria to the controversial Myriad Genetics case that determined human genes cannot be patented, we explore the fascinating legal battles that shaped biotech innovation. We journey through courtrooms worldwide where judges grappled with unprecedented questions: Can you patent a cloned sheep? Should farmers be allowed to replant patented seeds? Does traditional knowledge about medicinal plants deserve protection from corporate "biopiracy"?The legal landscape continues evolving, with a brand new WIPO treaty requiring disclosure of genetic resources' origins in patent applications. This represents a major shift toward transparency and fairness, especially for communities whose biodiversity and traditional knowledge have contributed to modern innovations.Whether you're a scientist, lawyer, entrepreneur, or simply curious about the legal frameworks governing emerging technologies, this episode offers crucial insights into how intellectual property systems are adapting to the brave new world where the line between invention and life itself becomes increasingly blurred. Subscribe to Intangiblia for more explorations of the fascinating intersection of law, technology, and innovation.Send us a text

In today's OncClub episode, we had the pleasure of speaking with Branden Moriarity, PhD; and Beau Webber, PhD, about a study evaluating neoantigen-reactive CISH knockout tumor-infiltrating lymphocyte (TIL) therapy in patients with metastatic gastrointestinal cancers. Dr Moriarity is an associate professor in the Division of Pediatric Hematology/Oncology, co-director of the Center for Genome Engineering and the Genome Engineering Shared Resource (GESR), and a member of the Center for Genome Engineering at the University of Minnesota in Minneapolis, where he is also a faculty member in the Department of Pediatrics; the Microbiology, Immunology and Cancer Biology (MICaB) PhD Graduate Program; the PhD Program in Molecular, Cellular, Developmental Biology and Genetics; the Cellular and Molecular Biology (CMB) Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Stem Cell Institute at the Masonic Cancer Center. Dr Webber is an associate professor in the Division of Pediatric Hematology/Oncology, co-director of the GESR, and a member of the Stem Cell Institute at the University of Minnesota Medical School, where he is also a faculty member in the Department of Pediatrics, the Molecular Pharmacology & Therapeutics Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Masonic Cancer Center. In our exclusive interview, Drs Moriarity and Webber discussed how targeting the CISH gene using CRISPR enhances T-cell function, key safety and efficacy findings from this study in 12 patients, and future research efforts that may focus on reducing manufacturing time and cost, as well as enhancing T-cell resilience. Check out the full OncClub subseries to see additional findings and insights from this research!

Mientras algunos científicos reciben aplausos por haber editado genéticamente a un bebé, otros científicos terminan en la cárcel ¿Por qué?!.He Jiankui, el científico chino que escandalizó al mundo en 2018 por editar genéticamente embriones humanos y dar lugar al nacimiento de las primeras bebés modificadas con CRISPR, vuelve a ser noticia. Esta vez, no por un nuevo experimento, sino por una declaración pública en la que acusa a la comunidad científica de hipocresía. Según Jiankui, otros investigadores están siendo aplaudidos por hacer lo mismo que él hizo, mientras que él fue encarcelado y duramente criticado. Pero ¿realmente hicieron lo mismo?En este video analizamos a fondo esta nueva controversia científica. Explicamos con claridad qué hizo exactamente He Jiankui, por qué su experimento fue considerado antiético, y qué diferencias existen con los trabajos más recientes que han sido bien recibidos por la comunidad científica. Profundizamos en conceptos clave como la edición genética en células germinales frente a células somáticas, el papel de los comités de ética, y los estándares internacionales que se deben cumplir para que un experimento en edición genética sea considerado responsable.La pregunta de fondo es incómoda pero necesaria: ¿existe una doble moral en la ciencia? ¿Estamos castigando a los pioneros mientras premiamos a quienes siguen caminos más aceptables, aunque similares? ¿O hay diferencias esenciales que justifican el trato desigual? Este caso nos obliga a reflexionar sobre los límites de la ética en la investigación genética, el avance de la tecnología CRISPR y la posibilidad real de intervenir en la línea germinal humana.He Jiankui no solo pone sobre la mesa su propia historia, sino que reabre un debate que involucra ciencia, ética, política y sociedad. ¿Fue un visionario incomprendido o alguien que cruzó una línea que no debía tocarse? Te invito a ver el video completo y a dejar tu opinión en los comentarios. ¿Estamos más cerca de aceptar la ingeniería genética en humanos? ¿Y quién decide qué es aceptable y qué no?

In this episode of the Healthy, Wealthy and Smart podcast, host Karen Litzy welcomes Elizabeth Chabe, MBA, MS, CEO of High Touch Group and author of "The Giant's Ladder, The Science Professional's Blueprint for Marketing Success." Elizabeth shares her expertise in marketing within the science and technology sectors, particularly focusing on biotech and MedTech. She discusses the challenges faced by innovators in getting their ideas noticed and provides insights on how to market groundbreaking work effectively. Listeners will gain valuable strategies for building brand awareness and achieving market traction, making this episode a must-listen for health and wellness professionals looking to amplify their impact. Join Tara and Elizabeth as they explore the intersection of science, storytelling, and strategy in marketing. Time Stamps:  [00:01:43] Marketing strategies for science professionals. [00:04:33] CRISPR and corporate strategy. [00:10:58] Fractional wet lab space. [00:12:08] Storytelling in scientific marketing. [00:15:50] Founders and product-market fit. [00:19:24] Selling scientific products effectively. [00:25:20] Business strategy vs. marketing gloss. [00:29:43] Science marketing for founders. [00:34:40] Marketing strategies for researchers. [00:38:04] Philanthropic support for dog rescue. [00:39:19] Importance of mission in business. More About Elizabeth:  ELIZABETH CHABE (MBA, MS) is an author, entrepreneur, and recognized strategic marketing consultant for science, engineering, and technology organizations. Her work has been featured in The New York Times, Popular Science, Entrepreneur, CNBC, Composites World, and 360Dx, among others.   As the founder and CEO of High Touch Group, Elizabeth oversees a team that develops marketing and PR strategies for advanced science, engineering, and technology organizations. Through High Touch Group's holistic, comprehensive marketing services, clients generate more leads, drive revenue, and elevate their brands into the global B2B space.  Her work as a strategic consultant has been instrumental to biotechnology, energy, advanced materials, advanced manufacturing, robotics, and automation companies.  Since her first business venture at the age of nine, Elizabeth has built and overseen countless successful research programs and marketing teams. As the former senior manager of digital and strategic marketing at the Jackson Laboratory (JAX), she developed the marketing strategies for its mouse model portfolio, model generation (CRISPR), and in vivo contract research services.  Prior to joining JAX, she oversaw global communications for the Advanced Structures and Composites Center in Maine. There, she managed projects including the center's offshore wind research program, the largest research and R&D program in Maine's history.  Since 2018, Elizabeth has been a governor-appointed director of the Maine Venture Fund.  An inveterate traveler, she splits her time between the US and developing world communities. She currently resides in Mexico with her husband and rescue dogs.  Resources from this Episode: July 17th Jane Q&A Webinar High Touch Group Elizabeth's Website Elizabeth on LinkedIn Giant's Ladder Book   Jane Sponsorship Information: Book a one-on-one demo here Mention the code LITZY1MO for a free month Follow Dr. Karen Litzy on Social Media: Karen's Twitter Karen's Instagram Karen's LinkedIn Subscribe to Healthy, Wealthy & Smart: YouTube Website Apple Podcast Spotify SoundCloud Stitcher iHeart Radio